Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Gross Profit (2016 - 2024)

Regenxbio (RGNX) has 11 years of Gross Profit data on record, last reported at $14.9 million in Q4 2024.

  • For Q4 2024, Gross Profit rose 35.73% year-over-year to $14.9 million; the TTM value through Dec 2024 reached $49.8 million, down 6.16%, while the annual FY2024 figure was $49.8 million, 6.16% down from the prior year.
  • Gross Profit reached $14.9 million in Q4 2024 per RGNX's latest filing, up from $11.8 million in the prior quarter.
  • Across five years, Gross Profit topped out at $375.6 million in Q4 2021 and bottomed at $6.5 million in Q1 2022.
  • Average Gross Profit over 5 years is $34.9 million, with a median of $13.7 million recorded in 2021.
  • Peak YoY movement for Gross Profit: surged 3257.14% in 2021, then plummeted 95.06% in 2022.
  • A 5-year view of Gross Profit shows it stood at $11.2 million in 2020, then soared by 3257.14% to $375.6 million in 2021, then tumbled by 95.06% to $18.6 million in 2022, then tumbled by 40.87% to $11.0 million in 2023, then skyrocketed by 35.73% to $14.9 million in 2024.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $14.9 million in Q4 2024, $11.8 million in Q3 2024, and $11.7 million in Q2 2024.